ISIS Pharmaceuticals About
ISIS Isis Pharmaceuticals, Inc. is a leading drug discovery and
development company, focused exclusively on the therapeutic target, RNA. Founded
in 1989, Isis' mission is to develop products from its RNA-based technologies,
such as antisense. Very little was known about antisense when the company
was first established, but its founders envisioned an opportunity to revolutionize
the pharmaceutical industry with a more efficient and targeted means of drug discovery.
Vitravene (fomivirsen) is the first antisense drug to achieve marketing
clearance. Vitravene treats a condition called cytomegalovirus (CMV) retinitis
in people with AIDS. Isis developed the drug and licensed the worldwide commercial
rights to Novartis Ophthalmics (formerly CibaVision.) Alicaforsen (ISIS 2302) --patients with
ulcerative colitis. ISIS 113715 --Diabetes ISIS 107248 --
Multiple Sclerosis ISIS 301012 Cardiovascular LY2181308 -- Cancer ATL-1101
-- Psoriasis More
on ISIS